Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solagran has announced that the Russian Agency for Patents and Trademarks has accepted a patent application submitted by the company covering the use of Bioeffective(r) A in the treatment of Helicobacter pylori infection. If awarded, the priority date for this patent will be 26 December, 2007.
Subscribe to our email newsletter
This patent application represents a very significant move strategically for Solagran. It constitutes the first step towards changing the status of Bioeffective(r) A from a complementary medicine substance, to a registered pharmaceutical effective in many indications that would each warrant a pharmaceutical classification.
The planned clinical trials to study the ability of Bioeffective(r) A to prevent and treat H.pylori infection, and at the same time treat pre-cancerous atrophic gastritis arising from H.pylori infection, plus further trials to establish its ability to prevent myelosuppression in cancer patients undergoing chemotherapy, and combined with known anti-oxidant, immune stimulating and microflora normalising properties, suggest a comprehensive role for Bioeffective(r) A in treating inflammatory conditions of the gastrointestinal tract and in assisting in the treatment of cancerous conditions.